-Reuters
HOOKIPA Announced Alternating 2-vector HB-202/HB-201 Therapy Showed Superior Tumor Response With 56% of Treated Patients Showing Target Lesion Shrinkage vs 38% of HB-201 Recipients in Head and Neck Cancer Trial; Data Presented at ASCO
HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human Papillomavirus 16-positive (HPV16+) head and neck cancer patients.
